+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Parkinson's Disease Drugs Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4390940
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 5


  • Abbvie
  • Allergan
  • GlaxoSmithKline
  • Janssen
  • Mylan Laboratories
  • Pfizer
  • MORE

According to an estimation, approximately 10 million people suffer from Parkinson's disease. This number keeps on increasing every year. At least one million of US citizens are suffering from this disease and this appends to around 60 thousand every year. A Parkinson's patient spends somewhere around $2,500 per year on medications to aid in ease of life. The disease prevalence increases with increase in the average age of the population.

The market will face corrosion due to entry of generics as well as due to patient expiries for key products, including Neupro, Azilect and Stalevo. The market however has a lot of unmet needs. Lack of a curative therapy in the current market is one of the reasons for continuous research and thus, new products are being launched every year. Four levodopa formulations might enter the market during this period thus causing market growth. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.

The main aim of a Parkinson's therapy is to balance diminished levels of dopamine in the subject's brain. This can be done by using Dopamine agonists and Monoamine Oxidase-B (MAO-B) Inhibitors for example. The Parkinson's disease drugs market have been, thus segmented based on the mechanism of action of the drugs used and geography. The Parkinson drugs have been segmented based on the Mechanism of their action on drug targets and include Dopamine agonists, Anti-cholinergics, Monoamine Oxidase-B Inhibitors, Acetylcholinesterase Inhibitors, NMDA Antagonists, COMT Inhibitors and Selective Serotonin Inverse Agonists (SSIA). The Dopamine Agonists includes the market for Carbidopa/levodopa (Sinemet, Sinemet CR, Rytary, Duopa), Apomorphine (Apokyn), Pramipexole (Mirapex, Mirapex ER), Ropinirole (Requip and Requip XL), Amantidine and Rotigotine (Neupro). The Anticholinergics class includes Trihecyphenidyl and Benztropine mesylate (Cogentin). The MAO-B Inhibitors class includes Selegiline (Eldepryl) and Raqsagiline (Azalect). The Acetylcholinesterage Inhibitors (Central) class includes Donepezil (Aricept), Rivastigmine (Exelon) and Galantamine (Razadyne, Razadyne ER). The NMDA Antagonists class includes Memantine (Namenda, Namenda XR). The COMT Inhibitors include Tolcapone (Tasmar) and Entacapone (Comtan) and Carbidopa, levodopa, and entacapone (Stalevo). Selective Serotonin Inverse Agonists (SSIA) include Pimavanserin (Nuplazid).

This report have been geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region have been further segmented into USA, Canada and Mexico. The Europe region have been sub-divided into Germany, France, UK, Spain, Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market have been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market have been subdivided into GCC countries, South Africa and rest of Middle East and Africa. The South American market have been segmented into Brazil, Argentina and rest of South America. North America accounts for the largest market share.

The current market lacks curative therapy and hence bringing innovative products and tapping the emerging economy will be a great opportunity for the market. The key players in the market are Merck & Co., Impax Laboratories, Abbvie Pharmaceuticals, Mylan Laboratories, Boehringer Ingelheim, GlaxoSmithKline, UCB, Somerset Pharmaceuticals, Teva NS, Pfizer, Novartis, Janssen, Allergan and Acadia.

Key Deliverables:

  • Market analysis for the Parkinson Drugs market, with region specific assessments and competition analysis.
  • Market definition along with the identification of key drivers and restraints.
  • Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale
  • Extensively researched competitive landscape section with profiles of major companies along with their market shares
  • Identification and analysis of the macro and micro factors that affect the Global Parkinson Drugs market
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
  • A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market
  • Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 5


  • Abbvie
  • Allergan
  • GlaxoSmithKline
  • Janssen
  • Mylan Laboratories
  • Pfizer
  • MORE

1.1 Study deliveratives
1.2 Market Definition
1.3 Review and forecasr period years
1.4 General Study Assumptions
1.5 Report Description

2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation


5.1 Current market scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Degree of competition
5.2.4 Threat of substitution
5.2.5 Threat of new entrants

6.1 Market Drivers
6.1.1 Increasing demand, higher prevalence of disease
6.1.2 Recent Drug Approvals
6.1.3 New entrants expected to balance generic intrusion
6.1.4 Increasing use of the MAO-B inhibitor
6.1.5 US Approval of existing drug in EU market
6.2 Market Restraints
6.2.1 Generic Competition to Key Therapies
6.2.2 Loss of patents for several drugs
6.2.3 Absence of revolutionary products in near future
6.3 Market opportunities
6.3.1 New Target Populations-shift from established markets to lesser developed markets
6.4 Key Challenges
6.4.1 Difficult development process

7.1.1 Dopamine Agonists Carbidopa/levodopa (Sinemet, Sinemet CR, Rytary, Duopa) Apomorphine (Apokyn) Pramipexole (Mirapex, Mirapex ER) Ropinirole (Requip and Requip XL) Amantadine Rotigotine (Neupro)
7.1.2 Anticholinergic Trihexyphenidyl Benztropine mesylate (Cogentin)
7.1.3 MAO-B inhibitors Selegiline (Eldepryl) Rasagiline (Azilect)
7.1.4 Acetylcholinesterase Inhibitors, Central Donepezil (Aricept) Rivastigmine (Exelon) Galantamine (Razadyne, Razadyne ER)
7.1.5 NMDA Antagonists Memantine (Namenda, Namenda XR)
7.1.6 COMT Inhibitors Tolcapone (Tasmar) Entacapone (Comtan) Carbidopa, levodopa, and entacapone (Stalevo)
7.1.7 Selective Serotonin Inverse Agonists (SSIA) Pimavanserin (Nuplazid)

8. Global Parkinson's disease market by Geography - Regional shares and forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America

9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships

10. Company Profiles
10.1 Merck & Co.
10.2 Impax Laboratories
10.3 Abbvie
10.4 Mylan Laboratories
10.5 Boehringer Ingelheim
10.6 GlaxoSmithKline
10.7 UCB
10.8 Somerset Pharmaceuticals Inc
10.9 Teva Neurosciences
10.10 Pfizer
10.11 Novartis
10.12 Janssen
10.13 Allergan
10.14 Acadia

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Merck & Co.
  • Impax Laboratories
  • Abbvie
  • Mylan Laboratories
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • Somerset Pharmaceuticals Inc
  • Teva Neurosciences
  • Pfizer
  • Novartis
  • Janssen
  • Allergan
  • Acadia
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4390940